LEXINGTON, MA – March 31, 2015 Quanterix Corporation, a leader in high definition diagnostics, delivering ultrasensitive single molecule measurement for the benefit of human health, today announced that RayBiotech, Inc., of Norcross, GA, has adopted its Simoa technology to deploy as part of their…
Quanterix and Beth Israel Deaconess Medical Center Publish Study on the Development and Validation of Digital ELISAs for Ultrasensitive Detection and Quantification of C. difficile toxins in Stool
LEXINGTON, MA – August 5, 2015 Quanterix Corporation, a leader in high definition diagnostics, today announced that the Journal of Clinical Microbiology has published a new study in which its Simoa (single molecule array) technology was used to develop a rapid, simple tool to allow diagnosis of…
ABL, Inc. Offers Quanterix Diagnostic Platform for Ultrasensitive Biomarker Detection Through Platine Pharma Services Subsidiary
January 14, 2016
Platine Pharma Services SAS (PPS), a majority owned subsidiary of ABL, Inc., is a preferred partner with Quanterix Corporation, providing new ultrasensitive assays using the single molecule measurement digital platform, Simoa.
Quanterix Opens Call for Proposals for Second Annual Accelerator Grant Program Focused on Oncology and Liquid Tumor Biopsy Technology
April 18, 2016
Quanterix announces the recipient of its first annual Accelerator Grant Program and a call for proposals for its second grant, focused on oncology research. The state-of-the-art Simoa Accelerator Lab is a dedicated laboratory environment for custom assay development and clinical sample testing.
Quanterix to Unveil Groundbreaking Neurodegenerative Disease Research and Strategic Partnership at Neuroscience 2016
November 15, 2016
Researchers will present key findings on the development of sensitive predictive biomarkers to establish therapeutic strategies for neurodegenerative diseases; Company will join forces with UmanDiagnostics to provide an ultrasensitive assay for Nf-L
May 16, 2017
CEO to discuss promising role of protein biomarkers in advancing detection and treatment of traumatic brain injury